Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Rxcell Inc. is currently managing 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct examiners and 2 distinct art units, indicating a broader reach within the patent office. This distribution suggests that the company is pursuing multiple technical paths or distinct inventions that have been categorized into different examination groups. Such a spread requires a coordinated management strategy to ensure consistency across the portfolio as it moves through different sectors of the Biotechnology & Pharmaceuticals division.
The busiest examiner for the portfolio is HUYNH, PHUONG N, who is assigned 1 pending office action. This indicates that the 2 pending office actions are distributed among the 2 distinct examiners involved in the company's current filings. The involvement of 2 distinct art units implies that the subject matter spans different specialized areas, which may lead to varying examination timelines. Practitioners must coordinate strategies across these different units and examiners to ensure consistent prosecution. This multi-examiner environment provides a diverse set of feedback that can help the company refine its overall intellectual property approach while navigating the specific requirements of HUYNH, PHUONG N.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HUYNH, PHUONG N | 1 | 65.7% | +53.6% |
| GU, QINHUA | 1 | 75.9% | +27.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17923070 | Hypoimmunogenic Cells and Uses Thereof in Immune Responses | HUYNH, PHUONG N | 34d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17923070 | Hypoimmunogenic Cells and Uses Thereof in Immune Responses | HUYNH, PHUONG N | 34d |
| 17913535 | Hypoimmunogenic Cells and Methods and Compositions for Their Production | GU, QINHUA | — |
| Art Unit | Apps |
|---|---|
| 1641 | 1 |
| 1633 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17923070 | Hypoimmunogenic Cells and Uses Thereof in Immune Responses | HUYNH, PHUONG N | 1641 | §102§103§112Other | Non-Final OA | 34d | Pending | Nov 03, 2022 |
| 17913535 | Hypoimmunogenic Cells and Methods and Compositions for Their Production | GU, QINHUA | 1633 | §103 | Final Rejection | — | Pending | Sep 22, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial